alexa Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience.
Healthcare

Healthcare

Journal of Community Medicine & Health Education

Author(s): Fassas A, Kimiskidis VK

Abstract Share this page

Abstract Based on the encouraging results of transplantation in animals with experimental autoimmune encephalomyelitis (EAE), small-scale phase I/II trials of autologous hematopoietic stem cell transplantation (autoHSCT) were initiated in 1995 for the treatment of severe cases of multiple sclerosis (MS). More than 200 patients with treatment-resistant multiple sclerosis have been transplanted so far, mainly in Europe and the USA. The results of these studies appear promising in terms of impact on MRI disease parameters and, to a lesser extent, clinical stabilization or even improvement. Despite concerns raised by the morbidity and mortality noted in the initial pilot studies, a controlled, randomized, phase III trial of autoHSCT against the best currently available treatment, i.e., mitoxantrone, seems justified and is under way. Copyright 2004 Elsevier B.V. This article was published in J Neurol Sci and referenced in Journal of Community Medicine & Health Education

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 23rd World Nursing and Healthcare Conference
    Jul 10-12, 2017, Golden Tulip Berlin - Hotel Hamburg, Berlin, Germany
  • 10th World Congress on Healthcare & Technologies
    Jul 17-18, 2017, Lisbon, Portugal
  • 30th Nursing and Healthcare Congress
    Aug 21-23, 2017, Toronto, Canada

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords